Use of prescription medications with a potential for fetal harm among pregnant women

Pharmacoepidemiology and Drug Safety

Volumn 15, Issue 8, 2006, Pages 546-554

  Andrade, Susan E ^a,b   Raebel, Marsha A ^b,c   Morse, Abraham N ^a,b   Davis, Robert L ^b,d   Chan, K Arnold ^b,e,f   Finkelstein, Jonathan A ^b,g   Fortman, Kris K ^b,h   Mcphillips, Heather ^b,d   Roblin, Douglas ^b,c   Smith, David H ^b,c   Yood, Marianne Ulcickas ^b,i   Platt, Richard ^b,e,g   Gurwitz, Jerry H ^a,b  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b HMO Research Network Center for Education and Research in Therapeutics   (United States)

^c KAISER PERMANENTE   (United States)

^d CENTER FOR HEALTH STUDIES   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h HEALTHPARTNERS RESEARCH FOUNDATION   (United States)

ⁱ HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

Fetal harm; Pregnancy; Prescription drugs

Indexed keywords

ALPRAZOLAM; AMINOPTERIN; ANDROGEN; ATENOLOL; BUSULFAN; CARBAMAZEPINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIETHYLSTILBESTROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOTAMINE; ESTRADIOL; ETRETINATE; FLUCONAZOLE; IODIDE; ISOTRETINOIN; LISINOPRIL; LITHIUM; METHYLPHENOBARBITAL; PHENYTOIN; PROPYLTHIOURACIL; PROSTAGLANDIN; TESTOSTERONE; TETRACYCLINE; THALIDOMIDE; THIAMAZOLE; TRIMETHADIONE; UNINDEXED DRUG; VALPROIC ACID; WARFARIN;

ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG USE; FEMALE; FETUS RISK; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; FREQUENCY ANALYSIS; GESTATIONAL AGE; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL DOCUMENTATION; MEDICAL EXPERT; OVULATION INDUCTION; PREGNANT WOMAN; PREMATURE LABOR; PRENATAL DRUG EXPOSURE; PRENATAL PERIOD; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERATOGENICITY; THIRD TRIMESTER PREGNANCY; UNITED STATES;

DRUG PRESCRIPTIONS; DRUG THERAPY; DRUG UTILIZATION; FEMALE; HEALTH MAINTENANCE ORGANIZATIONS; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PREGNANCY; PRESCRIPTIONS, DRUG; TERATOGENS; UNITED STATES;

EID: 33748373576     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1235     Document Type: Article

References (18)

1. National Center on Birth Defects and Developmental Disabilities. 2002 Report on the Metropolitan Atlanta Congenital Defects Program. Available at: http://www.cdc.gov/ncbddd/bd/bdsurv.htm. Accessed 11 January 2005.
2. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med 1998; 338: 1128-1137.
3. Lo WY, Friedman JM. Teratogenicity of recently introduced medications in human pregnancy. Obstet Gynecol 2002; 100: 465-473.
4. Mitchell AA. Systematic identification of drugs that cause birth defects - a new opportunity. N Engl J Med 2003; 349: 2556-2559.
5. Andrade SE, Gurwitz JH, Davis RL, et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398-407.
6. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol 2004; 18: 106-111.
7. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735-1736.
8. Malm H, Martikainen J, Klaukka T, Neuvonen P. Prescription of hazardous drugs during pregnancy. Drug Safe 2004; 27: 899-908.
9. Olesen C, Sorensen HT, de Jong-van den Berg L, Olsen J, Steffensen FH, and the Euromap Group. Prescribing during pregnancy and lactation with reference to the Swedish classification system: a population-based study among Danish women. Acta Obstet Gynecol Scand 1999; 78: 686-692.
10. Schirm E, Meijer WM, Tobi H, de Jong-van den Berg LTW. Drug use by pregnant women and comparable non-pregnant women in The Netherlands with reference to the Australian classification system. Eur J Obstet Gynecol 2004; 114: 182-188.
11. Briggs GG, Freeman RK, Yaffe SJ. A Reference Guide to Fetal and Neonatal Risk - Drugs in Pregnancy and Lactation(5th edn). Lippincott Williams & Wilkins: Philadelphia, 1998.
12. Scialli AR, Buelke-Sam JL, Chambers CD, et al. Communicating risks during pregnancy: a workshop on the use of data from animal developmental toxicity study in pregnancy labels for drugs. Birth Defects Res 2004; 70: 7-12.
13. TERIS Teratogen Information System. Available at: http:// depts.washington.edu/~terisweb/teris/. Accessed 31 May 2005.
14. Pregnancy Risk Assessment Monitoring System (PRAMS): PRAMS and Unintended Pregnancy. Available at: http://www.cdc.gov/PRAMS/UP.htm Accessed 19 January 2006.
15. Doering PL, Boothby LA, Cheok M. Review of pregnancy labeling of prescription drugs: is the current system adequate to inform of risks? Am J Obstet Gynecol 2002; 187: 333-339.
16. REPROTOX, An Online Reproductive Toxicology Resource. Available at: http://reprotox.org/ Accessed 31 May 2005.
17. Raebel MA, Ellis JL, Andrade SE. Evaluation of gestational age and admission date assumptions used to determine prenatal drug exposure from administrative data. Pharmacoepidemiol Drug Saf 2005; 14: 829-836.
18. Lagoy CT, Joshi N, Cragan JD, Rasmussen SA. Medication use during pregnancy and lactation: an urgent call for public health action. J Womens Health 2005; 14: 104-109.